Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, implies the current undervaluation of the stock.

This reduction of the stake means that Watson now owns 133,730 shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) directly and 80,136 shares indirectly through a custodial account for his minor children and the David O. Watson Irrevocable Trust of 2023. With that being said, the execution of the sale was under a pre-arranged 10b5-1 trading plan.

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday

A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds.

Some analysts believe that if you hold this stock, you need to have some patience. They argue that the significant FCF potential of SYFOVRE and EMPAVELI can’t be overlooked, with the market for SYFOVRE anticipated to exceed $1 billion in annual sales by 2028. EMPAVELI, on the other hand, is undergoing trials for additional indications and is expected to contribute to EBITDA positivity by 2026.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a Massachusetts-based commercial-stage biopharmaceutical company that discovers and commercializes novel therapeutic compounds for underserved diseases. Incorporated in 2009, the company has a license agreement with Swedish Orphan Biovitrum AB (publ) and Beam Therapeutics Inc.

While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.